SOPHiA GENETICS Reports Second Quarter 2024 Results
Strength in U.S. Growth Offset by Challenges in BioPharma and EMEA; Strong Cost Management Buffers Loss
SOPHiA GENETICS Announces L’hôpital Universitaire Avicenne is Live on SOPHiA DDM™
OncoHelix is the first laboratory in Canada to adopt MSK-ACCESS® powered with SOPHiA DDM™
Webinar Series – Episode 2: Decoding Complexity: Advanced Techniques for Detecting Low Allele Frequency Variants
Decoding Complexity - Overcoming Real-World Challenges in Variant Analysis Join us for the second episode of our webinar series, where we delve deeper into the complexities of variant analysis. Our esteemed bioinformatics experts will share practical solutions to...
Unlocking precision medicine through high-throughput sequencing in pharmacogenetics: RNPGx experience
Join us for an enlightening webinar on the evolution of pharmacogenetics, from its historical roots to the impact of groundbreaking innovations and the establishment of specialist foundations. We will explore the introduction of crucial guidelines and annotations...
SOPHiA GENETICS Announces Expanded Relationship with Canada-Based OncoHelix
OncoHelix is the first laboratory in Canada to adopt MSK-ACCESS® powered with SOPHiA DDM™
Society of Genetics of Brazil Congress
The SBG Congress in Brazil, organized by the Brazilian Society of Genetics is a prestigious event that gathers leading scientists and researchers in the field of genetics. This annual congress provides a platform for the presentation of cutting-edge research,...
SOPHiA GENETICS to Announce Financial Results for Second Quarter 2024 on August 6, 2024
BOSTON, United States and ROLLE, Switzerland, July 23, 2024 — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the second quarter of fiscal year 2024...
POSTER SPOTLIGHT: The Validation of a Homologous Recombination Deficiency Assay into Clinical Practice within the NHS
In this piece, we talked to the two presenters of the poster “The Validation of a Homologous Recombination Deficiency Assay into Clinical Practice within the NHS”, Elizabeth Ratsma, Pre-Registration Clinical Scientist – Cancer Genomics and Charlotte Flanagan, PhD, Innovation Lead, from The Royal Marsden NHS Foundation Trust. The poster was recently presented at the ESMO Gynaecological Cancers Congress 2024 in Florence, Italy. Read the full spotlight:
World Clinical Biomarkers & CDx Boston
We're back at World Clinical Biomarkers & CDx Boston! Join us to explore how you can harness the power of decentralization to drive global health equity. With our universal, scalable and technology-agnostic platform now serving 750 customers across 72...
What Healthcare Institutions need to know about the IVDR transition
Let’s answer some of the most pressing questions about IVDR compliance in practice and explore how CE-IVD certified software solutions can help.
India-Based Dhiti Omics is Now Live on SOPHiA DDM™
The diagnostics company has implemented the SOPHiA DDM™ Platform to enhance its solid tumor testing Boston, MA and Rolle, Switzerland, July 4, 2024 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in...
